[1]Patent:WO2010/121007,2010,A1.Locationinpatent:Page/Pagecolumn5;14-15
Title: Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Journal: Investigational new drugs 20120601
Title: Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Journal: PloS one 20120101
Title: STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells.
Journal: Biochemical and biophysical research communications 20111216
Title: Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
Journal: Archives of otolaryngology--head & neck surgery 20110501
Title: Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
Journal: International journal of oncology 20110101
Title: The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.
Journal: BMC cancer 20110101
Title: IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.
Journal: Cell cycle (Georgetown, Tex.) 20100901
Title: Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Journal: Cancer research 20100315
Title: The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.
Journal: Molecular cancer 20100101
Title: A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Journal: Molecular cancer 20100101
Title: Bill MA, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer. 2010 Jun 25;9:165.
Title: Lin L, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreaticand breast cancer cells. Cancer Res. 2010 Mar 15;70(6):2445-54.